Key facts
- This page summarizes Todd C. Davis's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2026, 17:10.
Todd C. Davis - 30 Jun 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- LGND
- Reported as of
- 30 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2026, 17:10:32 UTC
- Prior SEC filing
- 15 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Todd C. Davis filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 06 Jul 2026.
Change
- Previous filing in this sequence was filed on 15 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001392029
Primary reporting owner
Davis Todd C
- Relationship
- Chief Executive Officer, Director
- Address
- 555 HERITAGE DRIVE, SUITE 200, JUPITER
- Signature
- By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
- Signature date
- 06 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LGND
transaction
Common Stock
Other
- Transaction value
- Shares
- +132
- Change %
- +0.07%
- Price
- $160.71*
- Shares after
- 199,513
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).